Rahul Jasuja, Ph.D. has been named vice president of corporate development at Idera Pharmaceuticals. Dr. Jasuja previously served as managing director, Life Sciences at MDB Capital Group, a life sciences and technology merchant and investment bank.
“Rahul brings extensive and relevant scientific understanding and experience in the capital markets to Idera,” commented Sudhir Agrawal, D.Phil., chief executive officer and chief scientific officer. “We welcome Rahul to our team and expect him to play a key role in the Company as we continue to advance our drug discovery and development programs with agonists, antagonists, and antisense targeted to toll-ike receptors (TLRs).”
Dr. Jasuja joined MDB Capital Group in 2004, leading its life sciences research effort as Senior Biotechnology Research Analyst. He conducted due-diligence on private companies and initiated research reports on several public biotechnology companies, including Idera. He previously worked in similar roles at Rodman & Renshaw and Techvest LLC.